Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Brain Metastases from Renal Cancer
NCT00814021Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Apr 2009
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in kidney cancer, sponsored by Institut Claudius Regaud. Primary endpoint: Objective Response Rate in the Brain at 12 weeks. Started Apr 2009; status: completed.
02
Drugs
sunitinib
03
Conditions
kidney cancer
Beyond the preview
Go deeper on NCT00814021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814021.